Valuation dashboard for Krystal Biotech, Inc. (KRYS) with P/E 39.88, P/B 7.17, EV/EBITDA N/A and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa.
Analysis Summary
Trailing-twelve-month margins: gross margin 93.3%, operating margin 44.9%, net margin 54.8%.
Balance sheet quality for KRYS: current ratio of 10.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 39.88 |
| Price / Book | 7.17 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $474.89 |
| vs Current Price | +40.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| KRYS | Krystal Biotech, Inc. | $9.9B | 39.88 | 7.17 | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $9.3B | 19.78 | -0.3% | |
| PCVX | Vaxcyte, Inc. | $8.5B | 3.10 | -37.6% | |
| ACLX | Arcellx, Inc. | $6.7B | 16.10 | ||
| PTGX | Protagonist Therapeutics, Inc. | $9.2B | 8.71 | -21.2% | |
| PTCT | PTC Therapeutics, Inc. | $5.6B | 21.7% | ||
| ALKS | Alkermes plc | $7.7B | 112.07 | 4.16 | |
| CRSP | CRISPR Therapeutics AG | $5.0B | 2.86 |
Price
| Price | $337.83 |
| Market Cap | $10.0B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Gross Margin | 93.34% |
| Operating Margin | 44.93% |
| Net Margin | 54.82% |
Related companies: ACLX · ALKS · ARWR · CRSP · MTSR · PCVX · PTCT
Explore sector: Healthcare · Biotechnology
More sections of KRYS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks